Skip to main content

Table 1 Baseline characteristics of untreated patients with early RA in the four treatment arms

From: Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis—a spin-off study of the NORD-STAR randomized clinical trial

N = 347 MTX + prednisone (n = 85) MTX + TNFi (n = 87) MTX + CTLA-4Ig (n = 92) MTX + IL-6Ri (n = 83) P-value
Age, yearsa 62 (21–81) 58 (21–79) 58 (18–82) 53 (25–79) 0.29
Female sexb 58 (68%) 58 (67%) 62 (67%) 57 (69%) 0.99
BMI, kg/m2a 26 (18–43) 25 (19–37) 26 (18–38) 25 (20–43) 0.11
Current smokerb 12 (14%) 20 (23%) 18 (20%) 22 (27%) 0.22
Autoantibody status      0.55
RF-ACPA-b 11 (13%) 10 (11%) 11 (12%) 4 (5%)
RF+ACPA-b 5 (6%) 6 (7%) 5 (5%) 9 (11%)
RF-ACPA+b 11 (13%) 14 (16%) 12 (13%) 17 (20%)
RF+ACPA+b 57 (67%) 57 (66%) 64 (70%) 53 (64%)
Symptom duration, daysa,c 142 (25–813) 144 (41–702) 170 (37–731) 170 (37–691) 0.29
CDAIa 30.7 (7.8–62.8) 27.9 (8.1–68.7) 29.5 (14–68.4) 26.8 (8.4–55.2) 0.33
DAS28-CRPa 5.2 (2.6–7.7) 5.1 (2.2–8.3) 5.1 (3.3–7.6) 5.0 (2.7–7.3) 0.21
DAS28-ESRa 5.6 (3.6–8.2) 5.6 (2.7–8.7) 5.5 (3.7–8.1) 5.3 (2.6–7.9) 0.23
SJC-66a 13 (2–42) 12 (2–34) 11 (2–41) 10 (1–27) 0.10
TJC-68a 15 (2–47) 15 (1–47) 14 (0–62) 13 (0–47) 0.55
CRP, mg/ a 16 (0.5–216) 14 (0.5–180) 11 (0.3–146) 8.4 (0.3–82) 0.19
ESR, mm/ha 31 (4-108) 32 (4–98) 28 (4–115) 24 (2–84) 0.14
PGA, mma 58 (2–87) 57 (13–100) 61 (19–100) 59 (9–100) 0.18
  1. Missing data from one patient regarding BMI, RF, IFN day 1, IFN week 24, CDAI week 24, PGA week 24, and ESR week 24; from two patients regarding CRP day 1 and DAS28-ESR week 24; from three patients regarding CRP week 24; from four patients regarding CDAI day 1 and DAS28-CRP week 24; and from five patients regarding ESR day 1 and DAS28-ESR day 1
  2. MTX methotrexate, TNFi certolizumab-pegol, CTLA-4Ig abatacept, IL-6Ri tocilizumab, BMI body mass index, RF rheumatoid factor, ACPA anti-citrullinated protein antibodies, CDAI clinical disease activity index, DAS28 disease activity score 28 joints, SJC-66 swollen joint count, 66 joints, TJC-68 tender joint count, 68 joints, CRP C-reactive protein, ESR erythrocyte sedimentation rate, PGA patient global assessment
  3. aMedian (range), Kruskal-Wallis followed by Dunn’s multiple comparison test
  4. bn (%), Fisher’s exact test
  5. cRetrospective patient-reported joint pain before RA diagnosis